Two more generic semaglutide products sit approved but unmarketed in Canada's drug database

Two additional generic semaglutide products, Aspen-Semaglutide and Apotex's Sevmia, are listed as approved in Health Canada's Drug Product Database but carry no market date as of July 28, 2026 ^[1]. That means neither product can yet be bought at a Canadian pharmacy counter, even though regulators have signed off on them.

Approval and marketing are two separate steps under Canada's system. A drug can sit in the database as "Approved" for months or longer before a company actually ships it to pharmacies ^[1]. Timing for an actual launch depends on manufacturing supply, whether provinces list the drug for coverage, and pricing negotiations that happen after approval ^[1].

The contrast with Dr. Reddy's generic semaglutide is stark. That product reached Canadian pharmacies on May 15, 2026, becoming the first generic version of the drug to actually be dispensed in the country ^[1]. Reporting elsewhere in the same news feed describes Canada as only the second country in the world to approve a generic semaglutide product, following Health Canada's initial nod to Dr. Reddy's ^[1]. As of early September 2026, three of nine generic semaglutide submissions under review by Health Canada had been approved, while eight other files remained under review ^[1].

Pricing in Canada is expected to change as more generics launch. Under the country's pCPA pricing structure, a first generic entrant is generally priced at 75 to 85 percent of the brand-name cost, but once three or more generics reach the market, prices are expected to drop to about 35 percent of brand pricing ^[1]. Separate reporting notes that once a third generic semaglutide product actually launches, Canadian benefit plans face a roughly 65 percent cut in list price ^[1], which is consistent with that same three-generic threshold.

Why it matters for patients

For patients and caregivers watching for cheaper semaglutide options in Canada, an "approved" listing in the government database is not the same as a drug being available at a pharmacy. Aspen-Semaglutide and Sevmia are both approved as of July 28, 2026, but neither has a market date, so patients cannot yet fill a prescription for either one ^[1]. Only Dr. Reddy's version has actually reached pharmacy shelves so far, starting May 15, 2026 ^[1].

This distinction matters for anyone budgeting around an expected price drop. The bigger price cuts tied to having three or more generics on the market have not yet been triggered, since Aspen-Semaglutide and Sevmia are not yet being sold ^{[1] [1]}. Patients hoping for lower generic prices may need to wait for actual launches, not just database approvals, before seeing meaningful savings at the pharmacy counter.

What happens next

Health Canada was still reviewing eight additional generic semaglutide submissions as of early September 2026, following Dr. Reddy's initial approval ^[1]. Separate reporting notes that Sandoz was targeting a Q3 2026 entry into the Canadian generic semaglutide and tirzepatide markets, and described Aspen as taking a Canada-first approach ^[1]. As more generics clear the approval stage and then actually reach pharmacies, the three-generic price threshold that triggers steeper discounts could be reached, though no specific date for that has been reported ^[1]. Patients and pharmacists will likely need to watch for market dates, not just approval listings, to know when new lower-cost options become available.